Combining multimodal analysis with tumor-specific 3D cell culture models

For an anticancer drug to be effective in patients, it first needs to overcome the protection conferred by the interaction between tumor cells and the extracellular matrix (ECM), stromal and immune cells, and secreted factors.

In this application note, Dr. Julia Kirshner, CEO of zPREDICTA, Inc., describes a multiplexed drug response analysis protocol that combines zPREDICTA’s r-Breast and r-mBreast 3D culture models, which aim to reconstruct the microenvironment of human and mouse mammary tumors, with multimodal readout on the Spark Cyto from Tecan.